v3.26.1
Summary of Significant Accounting Policies - Summary of Segment Information for Revenue, Significant Operating Expenses and Other Income (Expense), and Net Loss (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Revenues:        
Total revenues, net $ 243,676 $ 110,565 $ 438,191 $ 227,198
Cost of revenues:        
Total cost of revenues 15,046 3,653 24,985 6,292
Total segment research and development 149,448 111,231 276,084 222,662
Selling, general and administrative 186,261 129,154 350,157 235,519
Restructuring, impairment, and related charges 0 805 0 1,375
Total operating costs and expenses 350,755 244,843 651,226 465,848
Loss from operations (107,079) (134,278) (213,035) (238,650)
Other income (expense), net:        
Interest income 6,659 3,898 12,905 9,283
Interest expense (13,278) (11,607) (26,220) (29,728)
Noncash interest expense on deferred royalty obligations [1] (41,345) (26,030) (81,218) [2] (50,050) [2]
Loss on extinguishment of debt 0 0 0 (21,155)
Net loss from equity method investments (6,435) (20,189) (24,718) (35,745)
Other income, net 5,587 6,548 9,840 14,779
Total other expense, net (48,812) (47,380) (109,411) (112,616)
Loss before income taxes (155,891) (181,658) (322,446) (351,266)
Provision for income taxes 0 2,100 0 2,100
Net loss (155,891) (183,758) (322,446) (353,366)
Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests 3,675 1,855 6,187 4,041
Net loss attributable to common stockholders of BridgeBio (152,216) (181,903) (316,259) (349,325)
Related Party        
Other income (expense), net:        
Noncash interest expense on deferred royalty obligations (5,575)   (10,936)  
Net product revenue        
Revenues:        
Total revenues, net 222,440 71,501 403,036 108,240
Cost of revenues:        
Total cost of revenues 10,528 2,848 18,260 4,882
License and services revenue        
Revenues:        
Total revenues, net 5,804 37,440 10,223 117,130
Royalty revenue        
Revenues:        
Total revenues, net 15,432 1,624 24,932 1,828
Cost of license, services, and royalty revenue        
Cost of revenues:        
Total cost of revenues 4,518 805 6,725 1,410
Reportable Segment        
Revenues:        
Total revenues, net 243,676 110,565 438,191 227,198
Cost of revenues:        
Total cost of revenues 15,046 3,653 24,985 6,292
Total segment research and development 149,448 111,231 276,084 222,662
Selling, general and administrative 186,261 129,154 350,157 235,519
Restructuring, impairment, and related charges 0 805 0 1,375
Total operating costs and expenses 350,755 244,843 651,226 465,848
Loss from operations (107,079) (134,278) (213,035) (238,650)
Other income (expense), net:        
Interest income 6,659 3,898 12,905 9,283
Interest expense (13,278) (11,607) (26,220) (29,728)
Noncash interest expense on deferred royalty obligations (41,345) (26,030) (81,218) (50,050)
Loss on extinguishment of debt 0 0 0 (21,155)
Net loss from equity method investments (6,435) (20,189) (24,718) (35,745)
Other income, net 5,587 6,548 9,840 14,779
Total other expense, net (48,812) (47,380) (109,411) (112,616)
Loss before income taxes (155,891) (181,658) (322,446) (351,266)
Provision for income taxes 0 2,100 0 2,100
Net loss (155,891) (183,758) (322,446) (353,366)
Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests 3,675 1,855 6,187 4,041
Net loss attributable to common stockholders of BridgeBio (152,216) (181,903) (316,259) (349,325)
Reportable Segment | Related Party        
Other income (expense), net:        
Noncash interest expense on deferred royalty obligations (5,575)   (10,936)  
Reportable Segment | Acoramidis for the treatment of ATTR-CM and primary prevention in asymptomatic carriers of a pathogenic TTR variant        
Cost of revenues:        
Total segment research and development 36,522 28,269 67,913 52,661
Reportable Segment | Infigratinib for achondroplasia and hypochondroplasia        
Cost of revenues:        
Total segment research and development 35,460 30,191 70,993 58,125
Reportable Segment | BBP-418 for LGMD2I/R9        
Cost of revenues:        
Total segment research and development 26,653 11,243 42,261 25,452
Reportable Segment | Encaleret for ADH1        
Cost of revenues:        
Total segment research and development 24,079 13,128 44,507 28,587
Reportable Segment | Other development programs        
Cost of revenues:        
Total segment research and development 6,763 10,536 13,523 21,966
Reportable Segment | Other research programs        
Cost of revenues:        
Total segment research and development 19,971 17,864 36,887 35,871
Reportable Segment | Net product revenue        
Revenues:        
Total revenues, net 222,440 71,501 403,036 108,240
Cost of revenues:        
Total cost of revenues 10,528 2,848 18,260 4,882
Reportable Segment | License and services revenue        
Revenues:        
Total revenues, net 5,804 37,440 10,223 117,130
Reportable Segment | Royalty revenue        
Revenues:        
Total revenues, net 15,432 1,624 24,932 1,828
Reportable Segment | Cost of license, services, and royalty revenue        
Cost of revenues:        
Total cost of revenues $ 4,518 $ 805 $ 6,725 $ 1,410
[1] Including related party amounts of $(5,575) and $(10,936), respectively, for the three and six months ended June 30, 2026 (as described in Note 9)
[2] Including a related party amount of $10,936 for the six months ended June 30, 2026 (as described in Note 9).